ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming
at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in
subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant
to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month
follow-up period.